CompletedPhase 2

Dexrazoxane to Protect Against Hemorrhagic STEMI

India50 participantsStarted 2025-08-30

Plain-language summary

This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).

Who can participate

Age range18 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adult (18 - 79 years).
✓. First STEMI (EMS/ER ECG ST-elevation) with TIMI 0 and primary PCI planned.
✓. Consent pathway available: Patient consent, Legally Acceptable Representative (LAR)
✓. CMR likely be feasible (no known MRI-unsafe implant or absolute MRI prohibition on record).

Exclusion criteria

✕. History of PCI or CABG within 1 year
✕. Known dialysis/ESRD (or documented eGFR \<30 if already in record); do not wait for new labs.
✕. Current anthracycline chemotherapy or active chest radiation (per patient/chart).
✕. On iron chelation now or documented iron-storage disease (hemochromatosis/thalassemia).
✕. Body weight \>140 kg (309 lb) by quick measurement/triage estimate.
✕. Planned urgent CABG instead of PCI
✕. Known pre-existing LVEF \<40% from recent records (if clearly available chart).
✕. Known pregnancy or breastfeeding (history or clearly documented)

What they're measuring

Change in Left Ventricular Ejection Fraction (LVEF)

Timeframe: From Baseline (48 to 72 hours post-PCI) to 3 Months

Intramyocardial Hemorrhage Burden (IMH %LV)

Timeframe: 48-72 hours post-primary PCI

Trial details

NCT IDNCT07502521

SponsorRohan Dharmakumar

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-02-15

View on ClinicalTrials.gov More Acute Myocardial Infarction (AMI) trials